Personal liberty safeguards restrict arrest after court-directed GST appearance, requiring interim release where authorities overreach pending proceed...
Alternative statutory remedy and delay bar GST writ challenges despite pending rectification, while distinct subject matter permits parallel proceedin...
Unverified Insight Portal Information Cannot Justify Reassessment Without a Verified Taxpayer-Specific Income-Escape Nexus or Demonstrated Application...
Assessing Officer jurisdiction after statutory transfer invalidates reassessment notices issued by transferor officers and nullifies resulting proceed...
Consequential appeal-effect orders must implement rectification deleting working-capital adjustments and reconsider the resulting arm's-length range c...
Discounted cash flow valuation protects share premium where projections are reasonable, while audited book expenses defeat unexplained-expenditure add...
Active Pharmaceutical Ingredients and bulk drugs qualify as "All Drugs and medicines" under the specific IGST rate entry where they retain their statutory identity as drugs under the Drugs and Cosmetics Act, 1940. Their import for formulation manufacture, testing, analysis, clinical research, clinical trials, bioavailability studies or bioequivalence studies does not alter that character. The description-based entry extends to goods under Chapter 30 or any other chapter, including APIs tariff-classifiable under Chapters 28 or 29. As the specific drugs entry prevails over general chemical entries, eligible APIs attract IGST at 5%, subject to exclusion where covered by the specified nil-rated entry.
Active Pharmaceutical Ingredients and bulk drugs qualify as "All Drugs and medicines" under the specific IGST rate entry where they retain their statutory identity as drugs under the Drugs and Cosmetics Act, 1940. Their import for formulation manufacture, testing, analysis, clinical research, clinical trials, bioavailability studies or bioequivalence studies does not alter that character. The description-based entry extends to goods under Chapter 30 or any other chapter, including APIs tariff-classifiable under Chapters 28 or 29. As the specific drugs entry prevails over general chemical entries, eligible APIs attract IGST at 5%, subject to exclusion where covered by the specified nil-rated entry.
Note: It is a system-generated summary and is for quick reference only.
TaxTMI 
TaxTMI 
